Cargando…
Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
BACKGROUND: Cancer is a somatic evolutionary disease and adenocarcinomas of the stomach and gastroesophageal junction (GC) may serve as a two-dimensional model of cancer expansion, in which tumor subclones are not evenly mixed during tumor progression but rather spatially separated and diversified....
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576943/ https://www.ncbi.nlm.nih.gov/pubmed/34749812 http://dx.doi.org/10.1186/s13073-021-00975-y |
_version_ | 1784595979533549568 |
---|---|
author | Röcken, Christoph Amallraja, Anu Halske, Christine Opasic, Luka Traulsen, Arne Behrens, Hans-Michael Krüger, Sandra Liu, Anne Haag, Jochen Egberts, Jan-Hendrik Rosenstiel, Philip Meißner, Tobias |
author_facet | Röcken, Christoph Amallraja, Anu Halske, Christine Opasic, Luka Traulsen, Arne Behrens, Hans-Michael Krüger, Sandra Liu, Anne Haag, Jochen Egberts, Jan-Hendrik Rosenstiel, Philip Meißner, Tobias |
author_sort | Röcken, Christoph |
collection | PubMed |
description | BACKGROUND: Cancer is a somatic evolutionary disease and adenocarcinomas of the stomach and gastroesophageal junction (GC) may serve as a two-dimensional model of cancer expansion, in which tumor subclones are not evenly mixed during tumor progression but rather spatially separated and diversified. We hypothesize that precision medicine efforts are compromised when clinical decisions are based on a single-sample analysis, which ignores the mechanisms of cancer evolution and resulting intratumoral heterogeneity. Using multiregional whole-exome sequencing, we investigated the effect of somatic evolution on intratumoral heterogeneity aiming to shed light on the evolutionary biology of GC. METHODS: The study comprised a prospective discovery cohort of 9 and a validation cohort of 463 GCs. Multiregional whole-exome sequencing was performed using samples form 45 primary tumors and 3 lymph node metastases (range 3–10 tumor samples/patient) of the discovery cohort. RESULTS: In total, the discovery cohort harbored 16,537 non-synonymous mutations. Intratumoral heterogeneity of somatic mutations and copy number variants were present in all tumors of the discovery cohort. Of the non-synonymous mutations, 53–91% were not present in each patient’s sample; 399 genes harbored 2–4 different non-synonymous mutations in the same patient; 175 genes showed copy number variations, the majority being heterogeneous, including CD274 (PD-L1). Multi-sample tree-based analyses provided evidence for branched evolution being most complex in a microsatellite instable GC. The analysis of the mode of evolution showed a high degree of heterogeneity in deviation from neutrality within each tumor. We found evidence of parallel evolution and evolutionary trajectories: different mutations of SMAD4 aligned with different subclones and were found only in TP53 mutant GCs. CONCLUSIONS: Neutral and non-neutral somatic evolution shape the mutational landscape in GC along its lateral expansions. It leads to complex spatial intratumoral heterogeneity, where lymph node metastases may stem from different areas of the primary tumor, synchronously. Our findings may have profound effects on future patient management. They illustrate the risk of mis-interpreting tumor genetics based on single-sample analysis and open new avenues for an evolutionary classification of GC, i.e., the discovery of distinct evolutionary trajectories which can be utilized for precision medicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-021-00975-y. |
format | Online Article Text |
id | pubmed-8576943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85769432021-11-10 Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine Röcken, Christoph Amallraja, Anu Halske, Christine Opasic, Luka Traulsen, Arne Behrens, Hans-Michael Krüger, Sandra Liu, Anne Haag, Jochen Egberts, Jan-Hendrik Rosenstiel, Philip Meißner, Tobias Genome Med Research BACKGROUND: Cancer is a somatic evolutionary disease and adenocarcinomas of the stomach and gastroesophageal junction (GC) may serve as a two-dimensional model of cancer expansion, in which tumor subclones are not evenly mixed during tumor progression but rather spatially separated and diversified. We hypothesize that precision medicine efforts are compromised when clinical decisions are based on a single-sample analysis, which ignores the mechanisms of cancer evolution and resulting intratumoral heterogeneity. Using multiregional whole-exome sequencing, we investigated the effect of somatic evolution on intratumoral heterogeneity aiming to shed light on the evolutionary biology of GC. METHODS: The study comprised a prospective discovery cohort of 9 and a validation cohort of 463 GCs. Multiregional whole-exome sequencing was performed using samples form 45 primary tumors and 3 lymph node metastases (range 3–10 tumor samples/patient) of the discovery cohort. RESULTS: In total, the discovery cohort harbored 16,537 non-synonymous mutations. Intratumoral heterogeneity of somatic mutations and copy number variants were present in all tumors of the discovery cohort. Of the non-synonymous mutations, 53–91% were not present in each patient’s sample; 399 genes harbored 2–4 different non-synonymous mutations in the same patient; 175 genes showed copy number variations, the majority being heterogeneous, including CD274 (PD-L1). Multi-sample tree-based analyses provided evidence for branched evolution being most complex in a microsatellite instable GC. The analysis of the mode of evolution showed a high degree of heterogeneity in deviation from neutrality within each tumor. We found evidence of parallel evolution and evolutionary trajectories: different mutations of SMAD4 aligned with different subclones and were found only in TP53 mutant GCs. CONCLUSIONS: Neutral and non-neutral somatic evolution shape the mutational landscape in GC along its lateral expansions. It leads to complex spatial intratumoral heterogeneity, where lymph node metastases may stem from different areas of the primary tumor, synchronously. Our findings may have profound effects on future patient management. They illustrate the risk of mis-interpreting tumor genetics based on single-sample analysis and open new avenues for an evolutionary classification of GC, i.e., the discovery of distinct evolutionary trajectories which can be utilized for precision medicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-021-00975-y. BioMed Central 2021-11-08 /pmc/articles/PMC8576943/ /pubmed/34749812 http://dx.doi.org/10.1186/s13073-021-00975-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Röcken, Christoph Amallraja, Anu Halske, Christine Opasic, Luka Traulsen, Arne Behrens, Hans-Michael Krüger, Sandra Liu, Anne Haag, Jochen Egberts, Jan-Hendrik Rosenstiel, Philip Meißner, Tobias Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine |
title | Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine |
title_full | Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine |
title_fullStr | Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine |
title_full_unstemmed | Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine |
title_short | Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine |
title_sort | multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576943/ https://www.ncbi.nlm.nih.gov/pubmed/34749812 http://dx.doi.org/10.1186/s13073-021-00975-y |
work_keys_str_mv | AT rockenchristoph multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT amallrajaanu multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT halskechristine multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT opasicluka multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT traulsenarne multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT behrenshansmichael multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT krugersandra multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT liuanne multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT haagjochen multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT egbertsjanhendrik multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT rosenstielphilip multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine AT meißnertobias multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine |